Drug Shortage Report for SODIUM ACETATE INJECTION, USP

Last updated on 2022-09-01 History
Report ID 151510
Drug Identification Number 02139529
Brand name SODIUM ACETATE INJECTION, USP
Common or Proper name Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) SODIUM ACETATE
Strength(s) 328MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 100 mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Other (Please describe in comments)
Anticipated start date
Actual start date 2022-05-16
Estimated end date 2022-10-31
Actual end date 2022-08-31
Shortage status Resolved
Updated date 2022-09-01
Company comments Fresenius Kabi Canada is pleased to advise that supply of our Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL will be available to our customers for an additional month. Allocations will be in place until August 31, 2022. Contract customers are allocated 100% of 100 mL demand plus 100% of 50 mL demand on a mL per mL basis (2 vials of 50 mL = 1 vial of 100 mL).
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v16 2022-09-01 French Compare
v15 2022-09-01 English Compare
v14 2022-08-21 French Compare
v13 2022-08-21 English Compare
v12 2022-07-29 French Compare
v11 2022-07-29 English Compare
v10 2022-05-17 English Compare
v9 2022-05-15 French Compare
v8 2022-05-15 English Compare
v7 2022-03-14 French Compare
v6 2022-03-14 English Compare
v5 2022-02-08 French Compare
v4 2022-02-08 English Compare
v3 2021-12-18 English Compare
v2 2021-12-17 French Compare
v1 2021-12-17 English Compare

Showing 1 to 16 of 16